Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of bifidobacterium animalis A6 in preparation of health-care product

A technology of animal bifidobacteria and health products, applied in preparations for in vivo experiments, medical preparations containing active ingredients, antibacterial drugs, etc., can solve the problems of poisoning and ineffective removal, and improve the intestinal tract Metabolism, improve the effect of kidney damage

Inactive Publication Date: 2020-05-12
CHINA AGRI UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, after dialysis, some of the toxins bound to proteins are still difficult to remove from the patient's body, and these substances will continue to have a toxic effect on the body
As current dialysis methods do not effectively remove protein-bound uremic toxins from the blood, new therapeutic strategies may be required to sustainably reduce these substances

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bifidobacterium animalis A6 in preparation of health-care product
  • Application of bifidobacterium animalis A6 in preparation of health-care product
  • Application of bifidobacterium animalis A6 in preparation of health-care product

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] Example 1 Effect of Animal Bifidobacterium A6 on Residual Kidney Function in 5 / 6 Nephrectomized Rats

[0074] 1. Materials and methods

[0075] 1.1 Experimental animals

[0076] 39 SPF grade Sprague Dawley (SD) rats, male, 6 weeks old, weighing 120-130 g, were purchased from Beijing Weitong Lihua Technology Co., Ltd., animal use license number: SCXK (Beijing) 2012-0001. They were raised in the SPF animal room of the China Agricultural University GMO Edible Safety Supervision, Inspection and Testing Center, with a room temperature of 22±2°C, a 12h light / dark cycle, and free access to water and food.

[0077] 1.2 Main reagents and formulas

[0078] The main reagents are shown in Table 1:

[0079] Table 1:

[0080]

[0081] Note: The rest of the unspecified reagents are domestic chemical or analytical reagents.

[0082] (1) Chloroacetaldehyde hydrate solution: Dissolve chloroacetaldehyde hydrate with sterile water before use to make a 40 mg / mL chloroacetaldehyde hydr...

Embodiment 2

[0139] Example 2 Target Analysis of Animal Bifidobacterium A6 on the Intestinal Flora of 5 / 6 Nephrectomized Rats

[0140] 2.1 Main reagents and formulas

[0141]

[0142] The remaining unspecified reagents were domestic chemical or analytical reagents.

[0143] (1) 50×TAE: 242g Tris, 57.1mL glacial acetic acid, 100mL 0.5mol / L EDTA, add water and dilute to 1L with ultrapure water, adjust the pH to 8.0.

[0144] (2) Tris-SDS: 250mL (200mM Tris-HCl, 80mM EDTA; pH 9.0), 50mL 10% SDS, mix well and set aside.

[0145] (3) Sodium acetate solution: adjust the pH to 5.2, dilute to a concentration of 3 mol / L, and sterilize at 121°C for 15 minutes for later use.

[0146] (4) Tris-EDTA: Adjust the pH of 10mmol / L Tris solution to 8.0 with 1mol / L HCl, add 1mmol / LEDTA, dilute to 1L with ultrapure water, and sterilize at 121°C for 15min.

[0147] (5) Chloroform / isoamyl alcohol (V / V=24:1): 96 mL of chloroform and 4 mL of isoamyl alcohol were mixed evenly and placed in a brown bottle for ...

Embodiment 3

[0212] Example 3 Clostridium difficile damages the residual kidney function of 5 / 6 nephrectomized rats

[0213] 3.1 Materials and methods

[0214] 3.1.1 Experimental animals

[0215] Twenty-four SPF grade SD rats, male, 6 weeks old, weighing 120-130 g, were purchased from Beijing Weitong Lihua Technology Co., Ltd., animal use license number: SCXK (Beijing) 2012-0001. They were raised in the SPF animal room of the China Agricultural University GMO Edible Safety Supervision, Inspection and Testing Center, with a room temperature of 22±2°C, a 12h light / dark cycle, and free access to water and food.

[0216] 3.1.2 Main reagents and formulas

[0217] Reagent name Reagent grade Reagent manufacturer

[0218] Enhanced Clostridium Medium Analytical Pure Qingdao High-tech Industrial Park Haibo Biotechnology Co., Ltd.

[0219] (1) Clostridium liquid culture medium: Take 38.0 g of the enhanced Clostridium medium and dissolve it in 1 L medium, and sterilize at 121° C. for 15 minutes be...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of bifidobacterium animalis A6 in preparation of a health-care product. The health-care product is used for relieving chronic kidney diseases. Experiment resultsdiscover that the bifidobacterium animalis A6 can achieve the effects of inhibiting generation of enterogenic uremia toxin and protecting the 5 / 6 renal resection rat residual kidney function by adjusting the intestinal microenvironment and improving intestinal metabolism; and the health-care product prepared from the bifidobacterium animalis A6 can be effectively used for relieving chronic kidneydiseases.

Description

technical field [0001] The present invention relates to the field of biopharmaceuticals. Specifically, the present invention relates to the use of Bifidobacterium animalis A6 in the preparation of health care products. More specifically, the present invention relates to the use of Bifidobacterium animalis A6 in the preparation of health care products and a method for screening drugs , a pharmaceutical composition and a drug combination for alleviating chronic kidney disease. Background technique [0002] Chronic kidney disease (CKD) can cause toxins such as urea in the blood to remain in the body without being metabolized by the kidneys. The accumulated toxins can flow through the body through the blood circulation and damage various organs of the body such as the kidneys, liver, brain, heart and intestines Road, etc., leading to a significant increase in the incidence of anemia, fractures, urinary tract infections, pneumonia, sepsis, and cardiovascular and cerebrovascular d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/745A61P13/12A61P31/04A61K49/00A61K31/7048A61K33/44
CPCA61K31/7048A61K33/44A61K35/745A61K49/0008A61P13/12A61P31/04A61K2300/00
Inventor 任发政张筱琳赵亮张明
Owner CHINA AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com